The American Society of Clinical Oncology(ASCO) annual meeting was held in June 3-7, 2016 in Chicago. This review will present a brief introduction of the progress in medical treatment for colorectal cancer in this annual meeting, such as preoperative neoadjuvant chemotherapy/concurrent chemoradiotherapy and postoperative adjuvant chemotherapy for advanced colorectal cancer, chemotherapy for inoperable advanced colorectal cancer, targeted therapy and immunotherapy.

Castleman disease (CD) is a rare polyclonal lymphoproliferative disorder characterized by enlarged hyperplastic lymph node(s). Unicentric Castleman disease (UCD) is an indolent condition often treated by local approaches. On the contrary, pa-tients with multicentric Castleman disease (MCD) have less favorable prognoses and require systemic treatments. Cytotoxic chemother-apy has been widely used to treat MCD with varying degrees of response because of the toxicity risk of the treatment. The pathogenesis remains unknown;however, most pieces of evidence to date point toward human herpes virus 8 (HHV-8) and deregulated overproduc-tion of interleukin (IL-6). Discovery of putative etiologic factors and targets in MCD, particularly HHV-8, CD20, and IL-6, has translat-ed to the use of rituximab, anti-IL-6-based, and antiviral therapy. Good results have been realized through targeting HHV-8 replication, CD20, and IL-6 pathways. In this article, we reviewed the classification, pathogenesis, and current treatments of CD and provided in-sights into future treatment strategies based on disease biology.

Objective To compare the efficacy and adverse reaction of teniposide (VM-26) plus carboplatin (TC regimen) and etoposide (VP-16) plus carboplatin (EC regimen) in treatment of newly diagnosed small cell lung cancer (SCLC), and the possible role of VM-26 on prevention of brain metastasis of SCLC. Methods A total of 102 previously untreated SCLC patients without brain metastasis were divided into VP-16 group received EC regimen (n=64) and VM-26 group received TC regimen(n=38). The carboplatin dosages in two groups were calculated by blood concentration-area under the curve(AUC)=5, and intravenous infusion of 1 h for the first day. In VM-26 group, VM-26 70 mg/m2+normal saline 500 mL was intravenously infused of 2 h for 1-3 days. VP-16 100 mg/m2+normal saline 500 mL was given to VP-16 group, 1 h for 1-3 days. Twenty-one day was for 1 treatment cycle. The curative effect, prognosis and adverse reaction were compared between two groups. Results The overall response rates (ORR) and disease control rates (DCR) were 78.9%(30/38) and 97.4%(37/38) in VM-26 group, respectively, and 76.6%(49/64) and 95.3%(61/64) in VP-16 group, respectively, with no significant differences between the two groups (χ2=0.078 and 0.283, P<0.05). The median progression-free survival (PFS) was 10 months (95%CI 7.4-12.6) in VM-26 group and 9 months (95%CI 6.4-11.6) in VP-16 group (χ2=0.029,P=0.866). The median overall survival (OS) was 18 months (95%CI 16.5-19.5) and 16 months (95%CI 9.9-22.1) in VM-26 group and VP-16 group (χ2=0.217,P=0.642), respectively. The survival rates for 1,2 and 3 years were 73.7%, 36.8%and 18.4%in VM-26 group, and 71.9%, 37.5%and 18.8%in VP-16 group, respectively, with no significant differences between the two groups (P>0.05). The brain metastasis rate was significantly higher in VP-16 group [43.8%(28/64)] than that of VP-26 group [21.1%(8/38),χ2=5.379,P=0.02). The adverse reactions were mainly grade 1/2 bone marrow suppression in two groups. Conclusion TC is a highly active regimen for treatment of SCLC. There is no difference in the ef?fectiveness and adverse reactions versus EC. Application of VM-26 can reduce the incidence of brain metastasis in SCLC patients.

Objective To investigate the positive expression of ATP binding cassette transporter protein F2 (ABCF2) in ovarian cancer tissue and its relationship with chemotherapy resistance.Methods 91 patients with ovarian cancer specimens were selected and 42 cases from the tumor 5cm adjacent tissues as normal controls, ABCF2 expression in each sample was detected by immunohistochemical staining , the relationship between ABCF2 expression and clinicopathological features of patients with ovarian cancer were analyzed .Results The positive expression rate of ABCF2 in ovarian cancer tissue was 68.13%, which was significantly higher than that in normal ovarian tissue (9.52%), and the difference was statistically significant (P<0.05).The positive expression of ABCF2 was not related to the age and organization type of ovarian cancer patients.The positive expression rate of ABCF2 in stage III~IV was 86.54%, which was significantly higher than that of phase I~II (43.59%), the difference was statistically significant (P<0.05). The positive expression rate of ABCF2 in patients with chemotherapy resistance was 88.89%, which was significantly higher than that in patients with chemotherapy sensitivity ( 59.38%) , and the difference was statistically significant ( P<0.05 ) .The results of Logistic regression analysis showed that ABCF2 positive expression was the independent influencing factor of ovarian cancer drug resistance (OR =4.586,95% CI:1.121 ~3.392,P<0.05). Conclusion ABCF2 is highly expressed in ovarian cancer, which may be associated with chemotherapy resistance in patients with ovarian cancer .

Objective To investigate the cell cycle of airway smooth muscle cells(ASMC) in asthmatic rats with airway remodeling and to explore a new method for the prevention and treatment of asthma.Methods The asthmatic rat models were established.The pathologic changes of inner airway wall and ASMC were determined by observing and analyzing the lung tissue sections stained with HE,and the cell cycle distribution of ASMC were analyzed by flow cytometry.Results The inner airway wall and smooth muscle layer were much thicker in rats of asthma group than those of control group(P

Methanotrophs could degrade methane and various chlorinated hydrocarbons. The analysis on methane monooxygenase gene cluster sequence would help to understand its catalytic mechanism and enhance the application in pollutants biodegradation. The methanotrophs was enriched and isolated with methane as the sole carbon source in the nitrate mineral salt medium. Then, five chlorinated hydrocarbons were selected as cometabolic substrates to study the biodegradation. The phylogenetic tree of 16S rDNA using MEGE5.05 software was constructed to identify the methanotroph strain. The pmoCAB gene cluster encoding particulate methane monooxygenase (pMMO) was amplified by semi-nested PCR in segments. ExPASy was performed to analyze theoretical molecular weight of the three pMMO subunits. As a result, a strain of methanotroph was isolated. The phylogenetic analysis indicated that the strain belongs to a species of Methylocystis, and it was named as Methylocystis sp. JTC3. The degradation rate of trichloroethylene (TCE) reached 93.79% when its initial concentration was 15.64 μmol/L after 5 days. We obtained the pmoCAB gene cluster of 3 227 bp including pmoC gene of 771 bp, pmoA gene of 759 bp, pmoB gene of 1 260 bp and two noncoding sequences in the middle by semi-nested PCR, T-A cloning and sequencing. The theoretical molecular weight of their corresponding gamma, beta and alpha subunit were 29.1 kDa, 28.6 kDa and 45.6 kDa respectively analyzed using ExPASy tool. The pmoCAB gene cluster of JTC3 was highly identical with that of Methylocystis sp. strain M analyzed by Blast, and pmoA sequences is more conservative than pmoC and pmoB. Finally, Methylocystis sp. JTC3 could degrade TCE efficiently. And the detailed analysis of pmoCAB from Methylocystis sp. JTC3 laid a solid foundation to further study its active sites features and its selectivity to chlorinated hydrocarbon.
Methylocystaceae ; classification ; metabolism ; Multigene Family ; Oxygenases ; genetics ; Phylogeny ; Polymerase Chain Reaction ; RNA, Ribosomal, 16S ; genetics ; Sequence Analysis, DNA ; Trichloroethylene ; metabolism

A new aporphine alkaloid, named fuzitine, was isolated from the tuber of Aconitum carmichaeli Debx. Its chemical structure was identified by the chemical, UV, IR, MS and NMR spectra analysis.

The over-activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamcyin (mTOR) pathway is closely related to the occurrence, development and clinical prognosis of malignant tumors. Taking this signal pathway as a target can effectively inhibit tumor progression. At present, the Food and Drug Administration of the United States has approved three drugs (CAL-101, BAY80-6946, IPI-145) for the treatment of recurrent and refractory indolent non-Hodgkin lymphoma, which demonstrates significant efficacy and a manageable safety profile.

Objective To optimize the HP-?-cyclodextrin(HP-?-CD)inclusion process condition for volatile oils from Anti-virus Oral Solution. Methods The process conditions were screened by determining the inclusion rate of volatile oils and the yield of inclusion compound,and by comparing the inclusion effect of supersonic method,saturated water solution method and grinding method.The optimum condition was investigated by the orthogonal test. The inclusion compound was identified by TLC,differential scanning calorimetry(DSC) and ultraviolet spectrophotometry (UV). Results The optimum preparation conditions for inclusion were established as follows: the proportion of volatile oils and HP-?-cyclodextrin was 1 ∶12,the inclusion temperature was at 45 ℃and the inclusion time was 3 hours .The inclusion rate of volatile oils was 66.71 %,and the yield of inclusion compound was 90.07 %. Conclusion The complex prepared under the optimized condition is stable and has a highest inclusion rate.

0.05),but these positive rates were notable decreased comparing with nPCR and immunohistochemistry techniques(P